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N-Terminal Pro-B-type Natriuretic Peptide Is Useful to Predict 
Cardiac Complications Following Lung Resection Surgery
Chang Young Lee, M.D.*, Mi Kyung Bae, M.D.*, Jin Gu Lee, M.D.*, 
Kwan-Wook Kim, M.D.*, In Kyu Park, M.D., Ph.D.*, Kyung Young Chung, M.D.*
Background: Cardiovascular complications are major causes of morbidity and mortality following non-cardiac thoracic 
operations. Recent studies have demonstrated that elevation of N-Terminal Pro-B-type natriuretic peptide 
(NT-proBNP) levels can predict cardiac complications following non-cardiac major surgery as well as cardiac 
surgery. However, there is little information on the correlation between lung resection surgery and NT-proBNP 
levels. We evaluated the role of NT-proBNP as a potential marker for the risk stratification of cardiac complications 
following lung resection surgery. Material and Methods: Prospectively collected data of 98 patients, who underwent 
elective lung resection from August 2007 to February 2008, were analyzed. Postoperative adverse cardiac events 
were categorized as myocardial injury, ECG evidence of ischemia or arrhythmia, heart failure, or cardiac death. 
Results: Postoperative cardiac complications were documented in 9 patients (9/98, 9.2%): Atrial fibrillation in 3, 
ECG-evidenced ischemia in 2 and heart failure in 4. Preoperative median NT-proBNP levels was significantly higher 
in patients who developed postoperative cardiac complications than in the rest (200.2 ng/L versus 45.0 ng/L, 
p=0.009). NT-proBNP levels predicted adverse cardiac events with an area under the receiver operating character-
istic curve of 0.76 [95% confidence interval (CI) 0.545∼0.988, p=0.01]. A preoperative NT-proBNP value of 160 
ng/L was found to be the best cut-off value for detecting postoperative cardiac complication with a positive pre-
dictive value of 0.857 and a negative predictive value of 0.978. Other factors related to cardiac complications by 
univariate analysis were a higher American Society of Anesthesiologists grade, a higher NYHA functional class and 
a history of hypertension. In multivariate analysis, however, high preoperative NT-proBNP level (＞160 ng/L) only 
remained significant. Conclusion: An elevated preoperative NT-proBNP level is identified as an independent pre-
dictor of cardiac complications following lung resection surgery. 
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INTRODUCTION
Cardiovascular complications are major causes of morbidity 
and mortality following non-cardiac thoracic operations [1]. In 
order to improve risk stratification and predictability of poten-
tial postoperative complications, various tools, such as revised 
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cardiac risk index (RCRI) or American College of Cardiolo-
gy/American Heart Association clinical risk factors, have been 
developed. These tools, however, cannot entirely replace a 
physician’s judgment for individual patients, particularly be-
cause of the complexity of these diagnostic tools and the lack 
of evidentiary support for their usefulness [2]. 
Therefore, simple and reliable method for identifying 
high-risk patients is necessary. It would allow a more tar-
geted and more cost-effective application of prophylactic 
interventions. It would also enable us to detect postoperative 
cardiac complications earlier through vigilant surveillance 
over selected high-risk patients. 
Cardiac natriuretic peptides including brain natriuretic pep-
tide (BNP) and N-terminal proBNP (NT-proBNP) have re-
cently emerged as potentially useful biomarkers in the diag-
nosis and prognostic stratification of heart failure patients as 
well as patients in other clinical settings such as liver cir-
rhosis or chronic renal failure [3,4]. More recently, it has 
been reported that these biomarkers are elevated in patients 
who experience perioperative cardiac complications following 
major cardiac and non-cardiac surgery [5-7]. However, there 
is little information on the correlation between lung resection 
surgery and NT-proBNP levels. 
We evaluated the role of NT-proBNP as a potential marker 
for the risk stratification of cardiac complications following 
lung resection surgery. 
MATERIAL AND METHODS
1) Study sample
One hundred one consecutive patients, who underwent 
elective lung resection surgery at our institute from August 
2007 to February 2008, were enrolled in this prospective 
study. Among them, three patients were excluded due to 
newly developed arrhythmia during anesthesia or significant 
hypotension related to perioperative bleeding because the ob-
jective of this study was to observe the net effect of pulmo-
nary resection on the development of cardiac complications. 
Thus, 98 patients constituted the study cohort. Twenty-six pa-
tients had a history of hypertension and 6 of them had been 
taking beta-blocker. Five patients out of seven patients who 
had a history of coronary artery occlusive disease had re-
ceived a percutaneous coronary artery intervention (PCI) or 
coronary artery bypass graft (CABG). All patients underwent 
elective lung resection surgery and had been free from major 
acute clinical events for at least two months before surgery. 
Patients were assessed prior to surgery by an attending anes-
thesiologist for American Society of Anesthesiologists (ASA) 
score. The study protocol was approved by the local 
Institutional Review Board. 
2) Data collection
Preoperative data collection encompassed patient demo-
graphic data, medical and surgical histories, preoperative 
medications, 12-lead electrocardiography (ECG), pulmonary 
function tests, and the data on renal and hepatic function. 
Preoperative blood samples were also obtained to measure se-
rum NT-proBNP level. The Revised Cardiac Risk Index 
(RCRI) was calculated from preoperative variables [8]. All 
patients remained under continuous ECG monitoring for at 
least 24 hours following surgery and underwent daily clinical 
cardiologic evaluations before discharge. All data was col-
lected prospectively.
3) Postoperative cardiac events
The occurrence of cardiac-related death or cardiac compli-
cations requiring treatment (myocardial injury, ECG evidence 
of ischemia or arrhythmia, or heart failure) before discharge 
was evaluated. Acute postoperative myocardial injury was de-
fined as the evidence of myocardial cell necrosis (Troponin T 
＞0.1 mg/L). ECG evidence of ischemia was defined as the 
development of T-wave inversion of greater than 2 mm, and 
ST segment deviation of greater than 2 mm in at least two 
contiguous chest leads or greater than 1 mm in at least two 
contiguous limb leads. Arrhythmia was defined as a new sus-
tained abnormal cardiac rhythm. All ECGs were analyzed by 
a cardiologist. Heart failure was defined as an occurrence of 
symptoms of congestive heart failure (orthopnea or dyspnea 
on exertions, venous distention, cardiomegaly, ankle edema, 
etc.) without the evidence of pneumonia. 
4) Serum NT-proBNP assays
To measure the serum NT-proBNP levels, blood samples 
were obtained 12 hours before and after the operation. Before 
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the preoperative blood sample, patients were asked to lie qui-
etly in the supine position to eliminate any potential effects 
of posture and exercise on serum NT-proBNP levels. 
NT-proBNP was assayed by a semiautomated analyzer 
(Elecsys-1010, Roche Diagnostics, Germany) using an electro-
chemiluminescence immunoassay kit (Elecsys NT-proBNP 
Test, Roche Diagnostics, Mannheim, Germany). 
5) Statistical analysis
Categorical data are presented as absolute values and 
percentage. Continuous variables are presented as the mean 
and standard deviation. Fisher’s exact test was used to test 
differences between two independent categorical data. 
Differences between two independent groups of continuous 
data were evaluated using Mann-Whitney U-test. To establish 
a NT-proBNP cut-off value with appropriate sensitivity and 
specificity, receiver operating characteristic (ROC) curves 
were plotted and the area under the curve was estimated. 
Linear logistic regression was used to test the cardiac event 
predictability of elevated NT-proBNP levels and other se-
lected parameters. A p-value less than 0.05 was considered 
significant. All statistical analyses were performed with the 
Statistical Package for Social Science (SPSS 12.0, Chicago, 
IL, USA).
RESULTS
There were 60 male and 38 female patients, and their 
mean age was 61.1±12.0 years. Twenty seven patients 
(23.5%) suffered from postoperative complications. Eight pa-
tients had pulmonary complications such as pneumonia, acute 
lung injury or bronchopleural fistula, and one patient suffered 
from chylothorax. Prolonged air leakage (air leakage ＞5 
days) occurred in 8 patients. Nine patients (9.2%) experienced 
cardiac complications following lung resection surgery. Atrial 
fibrillation occurred in 3 patients, ischemic change requiring 
vasodilator therapy in 2 patients, and heart failure in 3 pa-
tients including one patient with simultaneous pneumonia. 
One patient had simultaneous atrial fibrillation and heart 
failure. 
All cardiac events occurred within a week after the 
operation. ECG changes were identified in 9 patients (5 with 
T-wave or ST segment abnormalities and 4 with new onset 
atrial fibrillation). All patients with atrial fibrillation were 
treated with antiarrhythmic agent. Among 5 patients with T 
wave or ST segment abnormalities, two were treated with 
vasodilator immediately after the operation. All of these five 
patients’ ECGs recovered to their preoperative state within 7 
days. Acute myocardial injury did not occur in any patient. 
Postoperative heart failure requiring inotropic agents oc-
curred in 4 patients. All of them suffered from oliguria, leg 
edema and dyspnea without the evidence of pneumonia on a 
chest X-ray. Notably, ejection fractions determined with echo-
cardiography decreased over 10% and ejection fractions were 
below 40% in 2 patients. 
The relationship between preoperative and postoperative 
NT-proBNP levels and postoperative cardiac complications is 
demonstrated in Table 1. 
In patients with cardiac complications, both preoperative 
and postoperative NT-proBNP median values were signifi-
cantly higher than in patients not experiencing cardiac com-
plications (Table 1). 
The areas under the ROC curve, which signifies the utility 
of preoperative and postoperative NT-proBNP in predicting 
cardiac complications following lung resection surgery, were 
0.76 [95% confidence interval (CI) 0.545∼0.988, p=0.01] 
and 0.82 (95% CI 0.626∼1.024, p=0.001), respectively (Fig. 
1). The value of 160 ng/L was found to be the single best 
cutoff point for preoperative NT-proBNP in predicting the de-
velopment of cardiac complications. A preoperative NT-pro-
BNP value of 160 ng/L carried a positive predictive value of 
0.857 and a negative predictive value of 0.978 for detecting 
postoperative cardiac complications. 
The univariate predictors for postoperative complications 
included a poor NYHA functional class (≥2), a history of 
hypertension, a higher ASA score (≥2) and higher NT-pro-
BNP (＞160 ng/L). In the multivariate analysis, only the pre-
operative NT-proBNP remained significant as a predictor for 
postoperative cardiac complications (Table 2).
DISCUSSION
In this study, preoperative serum NT-proBNP was indicated 
as an independent predictor for cardiac complications follow-
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Table 1. Clinical and demographic characteristics of patients with or without postoperative cardiac complications 
Patient characteristics
Patients with postoperative 
cardiac complications (n=9)
Patients without postoperative 
cardiac complications (n=89)
p-value
Male
Age median
Smoking status
  Never
  Former
  Current
History of hypertension
Use of beta-blocker
CAD
Prior CABG or PCI
Creatintine
RCRI≥3
NYHA class≥2
ASA grade≥2
LVEF, % median
FEV1, % predicted
Type of operation
  Pneumonectomy
  Bilobectomy
  Lobectomy
  Segmentectomy
VATS
Estimated blood loss (mL), median
NT-pro BNP (ng/L) 
  Preoperative, median
  Postoperative, median
7 (77.8%)
69 (57∼78)
2 (22.2%)
6 (66.6%)
1 (11.1%)
6 (66.7%)
1 (11.1%)
2 (22.2%)
1 (11.1%)
0.9 (0.6∼1.9)
2 (22.2%)
6 (66.7%)
8 (89%)
60.0 (31.0∼69.0)
81.7 (44.7∼89.8)
2 (22.2%)
2 (22.2%)
4 (44.4%)
1 (11.1%)
3 (33.3%)
150 (0∼900)
200.2 (21.6∼1,722.0)
674.6 (45.2∼1,932.0)
53 (59.6%)
65 (15∼77)
35 (39.3%)
20 (22.5%)
34 (38.2%)
20 (22.5%)
8 (9.0%)
5 (5.6%)
4 (4.5%)
0.8 (0.6∼1.8)
5 (5.6%)
5 (5.6%)
46 (52%)
65.0 (28.0∼73.0)
81.9 (51.4∼96.8)
6 (6.7%)
12 (13.5%)
66 (74.2%)
5 (5.6%)
36 (40.4%)
200 (50∼1,500)
45.0 (10.6∼355.4)
190.2 (40.1∼1,397.0)
0.287
0.012
0.253
0.004
0.448
0.067
0.390
0.226
0.067
0.001
0.039
0.227
0.874
0.108
0.477
0.061
0.515
0.679
0.042
0.009
0.001
CAD=Coronary artery disease; CABG=Coronary artery bypass graft; PCI=Percutaneous coronary intervention; RCRI=Revised Cardiac 
Risk; Index=NYHA, New York heart association; ASA=American society of anesthesiologists; LVEF=Left ventricular ejection frac-
tion; FEV1=Forced expiratory ventilation in 1 second; VATS=Video assisted thoracoscopic surgery.
Fig. 1. ROC curve for preoperative NT-proBNP (solid line) and 
postoperative NT-proBNP (dashed line). ROC=Receiver operating 
characteristic.
ing lung resection surgery by a multivariate analysis.
Cardiac complications occur frequently after lung resection 
surgery. Atrial fibrillation is the most common cardiovascular 
complications after thoracic surgery, with a reported incidence 
of 8% to 20% after lobectomy and up to 40% after pneumo-
nectomy [8,9]. These events contribute significantly to mor-
bidity, mortality and the increased cost of medical care. 
Hence, a proactive approach for identifying patients with a 
higher risk for these complications is necessary. 
Various tools have been developed to improve risk strat-
ification and predictability for postoperative complications. 
The most widely used risk assessment tool for predicting ma-
jor cardiac complications after non cardiac surgery is the re-
vised cardiac risk index (RCRI) [2]. The six independent risk 
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Table 2. Univariate and multivariate analysis for predictors of adverse cardiac outcome using logistic regression
Patient characteristics
Odds ratio (95% CI)
univariate
p-value
Odds ratio (95%CI)
multivariate
p-value
NT-proBNP ＞160 ng/L
Age (＞65 years)
Hypertension
Beta-blocker use
NYHA class≥2
RCRI≥3
ASA score≥2
Ejection fraction
Estimated blood loss≥500 mL
2.28 (1.95∼2.66)
1.09 (0.96∼1.24)
1.21 (1.06∼1.37)
1.08 (0.85∼1.38)
1.67 (1.43∼1.94)
1.23 (0.98∼1.54)
1.13 (1.01∼1.27)
0.98 (0.97∼1.01)
1.06 (0.90∼1.25)
＜0.001
0.195
0.004
0.517
＜0.001
0.066
0.033
0.135
0.475
1.88 (1.21∼2.90)
0.98 (0.89∼1.08)
1.12 (0.85∼1.46)
0.94 (0.66∼1.32)
1.21 (0.77∼1.90)
1.18 (0.83∼1.67)
0.87 (0.61∼1.25)
1.00 (0.99∼1.01)
1.11 (0.74∼1.66)
0.008
0.195
0.389
0.690
0.384
0.338
0.427
0.937
0.592
NYHA=New York heart association; RCRI=Revised cardiac risk index; ASA=American society of anesthesiologists.
predictors in the index include ischemic heart disease, heart 
failure, cerebrovascular disease, chronic renal insufficiency 
(serum creatinine level＞2 mg/dL), insulin-dependent diabe-
tes mellitus, and high-risk surgery. Patients can be classified 
as low (zero or one risk factor), intermediate (two factors), or 
high (three or more factors) risk groups with corresponding 
postoperative cardiac complication rates of approximately 1%, 
5%, and 10%, respectively. However, RCRI may not always 
be precise in predicting postoperative cardiac complications. 
In our study, a high RCRI score (RCRI≥3) was not asso-
ciated with postoperative cardiac complications (Table 2). 
Many surgeons utilize various preoperative imaging studies 
for cardiac function (including i.e. echocardiography, mag-
netic resonance imaging, and radionuclide studies) to evaluate 
left ventricular (LV) function [10-13]. It is generally agreed 
that depressed LV function is associated with a higher risk of 
postoperative cardiac complications, but it remains debatable 
whether these tests provide additional information to routine 
clinical evaluation [14]. Halm et al. [10] reported that an LV 
ejection fraction of less than 40% was associated with post-
operative cardiac complications, particularly heart failure. 
However, our study demonstrated that the LV ejection frac-
tion did not correlate with the risk of postoperative cardiac 
complications after lung resection surgery (Table 2). 
It has been suggested that NT-proBNP levels could be a 
useful markers of left ventricular dysfunction in both sympto-
matic and asymptomatic patients. Plasma levels of atriuretic 
peptides have been reported to be elevated not only in pa-
tients with advanced heart failure or acute myocardial in-
farction, but also in other clinical settings such as liver cir-
rhosis or chronic renal failure. Recently, several reports re-
garding the correlation between NT-proBNP and cardiac com-
plications following major cardiac and non-cardiac surgery 
have been published. However, there is little information on 
the correlation between lung resection surgery and 
NT-proBNP levels. Cardinale et al. [15] recently demon-
strated that NT-proBNP is a strong independent predictor of 
postoperative atrial fibrillation in patients undergoing thoracic 
surgery for lung cancer. However, other cardiac complications 
were not evaluated in that study, and the comparison of the 
predictability of adverse cardiac outcomes between NT-proBNP 
and other risk factors was not elucidated.
Our study took into account various cardiac complications 
(including atrial fibrillation), and demonstrated that preope-
rative NT-proBNP levels were an independent predictor of 
the adverse outcomes by a multivariate analysis, after adjust-
ing other risk factors such as revised cardiac risk index 
which is most widely used for predicting major cardiac 
complications. This finding carries important clinical im-
plications, and may enable us to accurately stratify patients 
according to their risk of adverse outcomes. Awareness of 
preoperative NT-proBNP levels in patients who are under-
going lung resection surgery may help preventing the occur-
rence of cardiac complications after surgery. Assessment of 
NT-proBNP levels may offer a simple and cost-effective 
means of identifying high-risk patients, and may benefit the 
patients by getting around invasive and costly preoperative 
work-up.
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There is no consensus on the cut-off value for abnormal 
NT-proBNP concentrations. When using the chemiluminescent 
kit from Roche Diagnostics, the upper 97.5 percentile level is 
identified as 155 ng/L for men and 84 ng/L for women under 
50 years of age. Between 50 and 65 years, the upper limit 
comes up to 222 ng/L for men and 194 ng/L for women. 
According to the studies in different clinical settings, the sug-
gested cut-off values of NT-proBNP ranged from lower than 
100 ng/L to higher than 1,000 ng/L [16-19]. We suggested a 
cut-off value of 160 ng/L for NT-proBNP, but this value may 
need further evaluation before clinical application. 
As mentioned above, NT-proBNP level increases in various 
clinical conditions such as left ventricular hypertrophy (LVH), 
left atrial enlargement or compensated heart failure. Lung re-
section, which may be a precipitating factor in patients with 
increased NT-proBNP level, brings a transient, but a sig-
nificant extent of, pressure load to the heart. We assume that 
this abrupt hemodynamic change may bring about ischemic 
change on ECG in patient with LVH, atrial fibrillation in pa-
tient with left atrial enlargement, and symptomatic heart fail-
ure in patient with compensated heart failure. 
In addition to preoperative measurements, we also checked 
NT-proBNP levels 12 hours after surgery. Postoperative NT- 
proBNP levels were also useful to identify the high-risk 
patients. When both preoperative and postoperative NT-pro-
BNP levels were integrated, the sensitivity of NT-proBNP in-
creased from 0.667 to 0.778. These findings suggest that both 
preoperative and postoperative elevation of NT-proBNP levels 
can predict cardiac complications for patients undergoing lung 
resection surgery. 
Our study had several limitations. Firstly, although NT-pro-
BNP and other preoperative parameters were collected pro-
spectively, the occurrence of cardiac complications was ana-
lyzed retrospectively. Thus, it is possible that some patients 
may have had very transient episodes of arrhythmia which 
went unnoticed. Secondly, only a small number of patients in 
a single center was enrolled in this study. Thirdly, we exam-
ined only one biologic marker. Presumably, further studies on 
other preoperative biologic markers may be necessary in pa-
tients with low NT-proBNP levels to improve sensitivity and 
positive predictive value of the preoperative assessment for 
the delineation of the patients with a higher risk of post-
operative cardiac events. 
CONCLUSION
Elevated preoperative NT-proBNP level is identified as an 
independent predictor for cardiac complications following 
lung resection surgery. This correlation may enable us to plan 
adequate treatments in advance, and to detect cardiac compli-
cations as early as possible through the monitoring of post-
operative NT-proBNP levels in selected high-risk patients. 
Further studies are necessary to support our observation, and 
to clarify the relationship between NT–proBNP levels and ex-
isting methods of risk stratification.
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